Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Australia's Inflation Eases in February but Core Pressures Persist 
Japan Eyes Oil Futures Intervention to Stabilize Yen Amid Middle East Crisis 
Japan's Private Sector Growth Slows in March Amid Rising Costs and Middle East Uncertainty 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
Asian Stocks Gain Amid Iran Conflict Uncertainty 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
South Korea's SK Chemicals has partnered with AstraZeneca's Korean affiliate in a contract manufacturing organization (CMO) agreement. SK Chemicals will produce and globally distribute Sidapvia, a new treatment for type 2 diabetes, combining leading active ingredients dapagliflozin and sitagliptin.
Under this agreement, SK Chemicals will be responsible for the manufacturing and global distribution of Sidapvia, a groundbreaking combination of Forxig (dapagliflozin) and sitagliptin. Sidapvia is indicated for adults aged 18 and older with type 2 diabetes, a condition characterized by improper insulin function and high blood sugar levels.
SK Chemicals and AstraZeneca have jointly developed this promising diabetes treatment. While SK Chemicals focuses on manufacturing and distribution, AstraZeneca will be the marketing authorization holder (MAH). They will handle country-specific licensing and marketing efforts, and South Korea has already granted licensing for Sidapvia, making it the first country to do so.
Sidapvia combines two active ingredients, Forxiga and sitagliptin, globally recognized as a leading SGLT-2 inhibitor and top-selling DPP-4 inhibitor. These ingredients work through different mechanisms of action to effectively lower blood glucose levels, offering a viable option for managing complications among diabetic patients.
Ahn Jae-hyun, the CEO of SK Chemicals, expressed utmost confidence in the company's pharmaceutical technology and production capabilities. These capabilities have paved the way for the supply of medicines to numerous countries, and Ahn emphasized the company's plans to foster diverse collaboration opportunities.
The collaboration between SK Chemicals and AstraZeneca began in early 2020, with AstraZeneca providing SK Chemicals with active pharmaceutical ingredients (APIs) and funding research for diabetes treatment development. Subsequently, SK Chemicals took over product research and development and conducted domestic clinical trials. With this new agreement as a starting point, SK Chemicals aims to expand the supply of Sidapvia in Korea and the global market.
This collaboration marks a significant milestone for SK Chemicals and AstraZeneca, solidifying their commitment to advancing diabetes treatment and improving the lives of millions of patients worldwide.
